MODIFICATION OF FEEDING BEHAVIOR

• US 20090209461A1
• Filed: 08/29/2008
• Published: 08/20/2009
• Est. Priority Date: 09/24/2001
• Status: Active Grant

• Current Assignee: Imperial Innovations Limited (Imperial College London), Oregon Health & Science University
• Original Assignee: Imperial College Innovations Ltd. (Imperial College London), Oregon Health & Science University
• Inventors: Batterham, Rachel Louise, Small, Caroline Jane, Butler, Andrew, Ghatei, Mohammad Ali, Bloom, Stephen Robert, Cowley, Michael, Cone, Roger, Low, Malcolm
• Granted Patent: US 8,217,001 B2
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.

Claims

1. A method for decreasing calorie intake, food intake or appetite in a human subject in need thereof, comprising peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject.

2. The method of claim 1, wherein the subject is overweight.

3. The method of claim 1, wherein the subject is obese.

4. The method of claim 1, wherein the subject is diabetic.

5. The method of claim 1, wherein peripherally administering PYY or the agonist thereof comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal or sublingual administration.

6. The method of claim 5, wherein peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject.

9. The method of claim 5, wherein peripherally administering the therapeutically effective amount of PYY or the agonist thereof comprises administration of about 0.5 to about 135 pmol per kilogram of body weight at least about 30 minutes prior to a meal.

10. The method of claim 1, further comprising administering a therapeutically effective amount of amfepramone (diethylpropion), phentermine, mazindol, phenylpropanolamine, fenfluramine, dexfenfluramine, or fluoxetine.

11. The method of claim 1, wherein the PYY or the agonist thereof is administered in an amount sufficient to decrease calorie intake for a period of at least about 2 hours.

12. The method of claim 1, wherein the PYY or the agonist thereof is PYY_3-36.

13. The method of claim 12, wherein the subject is human PYY_3-36 is administered by an oral, subcutaneous, intracisternal, transdermal or topical route.

14. The method of claim 1, wherein the PYY agonist comprises a molecule that specifically binds the Y2 receptor.

7-8. -8. (canceled)

15-104. -104. (canceled)

105. A method for treating obesity in a human subject in need thereof, comprising peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject.

106. The method of claim 105, wherein the subject is diabetic.

107. The method of claim 105, wherein peripherally administering PYY or the agonist thereof comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal or sublingual administration.

108. The method of claim 107, wherein peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject.

109. The method of claim 107, wherein peripherally administering PYY or the agonist thereof comprises administering about 72 pmol per kilogram body weight of the subject.

110. The method of claim 107, wherein peripherally administering the therapeutically effective amount of PYY or the agonist thereof comprises administering PYY or an agonist thereof to the subject in a multitude of doses, wherein each dose in the multitude of doses comprises administration of about 0.5 to about 135 pmol per kilogram of body weight at least about 30 minutes prior to a meal.

111. The method of claim 105, further comprising administering a therapeutically effective amount of amfepramone (diethylpropion), phentermine, mazindol, phenylpropanolamine, fenfluramine, dexfenfluramine, or fluoxetine.

112. The method of claim 105, wherein the PYY or the agonist thereof is administered in an amount sufficient to decrease calorie intake for a period of at least about 2 hours.

113. The method of claim 105, wherein the PYY agonist comprises a molecule that specifically binds the Y2 receptor.

114. The method of claim 105, wherein the PYY or the agonist thereof is PYY_3-36.

115. The method of claim 114 wherein the PYY_3-36 is administered by an oral, subcutaneous, intracisternal, transdermal or topical route.